Eine Studie zur Überprüfung der Lebergesundheit bei Jungen mit XLMTM, einer schwerwiegenden genetischen Muskelerkrankung (EXCEL)
Eine nicht-interventionelle, epidemiologische Studie zu XLMTM und der klinischen Expression in der Leber
XLMTM (X-linked myotubular myopathy) is a serious genetic muscle condition. It is caused by changes in the MTM1 gene which stops or slows down normal muscle development, causing severe muscle weakness. There is currently no cure for XLMTM. Ongoing care is needed to manage symptoms and prevent further medical problems from this condition.
Recent research shows that individuals with XLMTM often have reduced bile flow which can affect liver and gallbladder health. Bile is a liquid made in the liver that helps digest fat. Ongoing liver health checks may help with the routine care of people with XLMTM.
There is a need to understand liver problems that develop in individuals with XLMTM over time. The main aim of the study is to learn how many boys with XLMTM have new cases of liver problems during the study.
This study is about collecting information only. This is known as an observational study. The individual's doctor decides on treatment, not the study sponsor (Astellas).
In this study, boys under 18 diagnosed with XLMTM will be followed for about 1 year. The health of their liver and gallbladder will be checked about every 6 weeks. This can be done at home, if preferred. A scan called a Fibroscan (also known as transient elastography) will check for signs of scarring in the liver (fibrosis) and the build-up of lipids. It is suggested that each boy will have a Fibroscan when they start the study and another scan when they complete the study.
This study will help understand liver, gallbladder, and bile duct issues in individuals with XLMTM over time. The goal is to improve their care and provide information to use in future clinical studies.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Astellas Gene Therapies
- Telefonnummer: 800-888-7704
- E-Mail: Astellas.registration@astellas.com
Studienorte
-
-
Ontario
-
Toronto, Ontario, Kanada
- Rekrutierung
- Site CA15001
-
-
-
-
California
-
Santa Monica, California, Vereinigte Staaten, 90401-2072
- Rekrutierung
- UCLA Neurological Services
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60611
- Rekrutierung
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02115
- Rekrutierung
- Boston Children's Hospital
-
-
Ohio
-
Cincinnati, Ohio, Vereinigte Staaten, 45229
- Rekrutierung
- Cincinnati Children's Hospital Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
- Rekrutierung
- Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15224
- Rekrutierung
- UPMC Children's Hospital of Pittsburgh
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84112
- Rekrutierung
- University of Utah
-
-
-
-
-
Leeds, Vereinigtes Königreich
- Rekrutierung
- Site GB44006
-
London, Vereinigtes Königreich
- Rekrutierung
- Site GB44003
-
Oxford, Vereinigtes Königreich
- Rekrutierung
- Site GB44005
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Approximately 50 male participants < 18 years of age with genetically confirmed XLMTM will be enrolled at specialist sites.
Beschreibung
Inclusion Criteria:
- Participant has a diagnosis of XLMTM resulting from a genetically confirmed mutation in the MTM1 gene based on genetic test reports.
- Participant requires some mechanical ventilatory support (e.g., ranging from 24 hours per day full-time mechanical ventilation, to non-invasive support such as continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP) during sleeping hours)
- Participant (as applicable) and/or parent(s)/carer is willing to comply with the recommended schedule of assessments.
Exclusion Criteria:
- Participant is currently enrolled in an interventional study designed to treat XLMTM.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Anzahl der Gruppen / Kohorten
Kohorten und Interventionen
Gruppe / KohorteGruppe / Kohorte |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Participants with XLMTM
Pediatric and adolescent participants with XLMTM. |
No investigational drug will be administered to participants in this study. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence rate of cholestasis
Zeitfenster: Up to Week 48
|
Calculated as the number of new cases of cholestasis over 48 weeks divided by total duration of follow-up for enrolled participants. |
Up to Week 48
|
|
Point prevalence of cholestasis
Zeitfenster: Day 1
|
Point prevalence of cholestasis is defined as the proportion of participants who have had at least 1 case of cholestasis prior to Day 1 (baseline). |
Day 1
|
|
Prevalence of cholestasis
Zeitfenster: Up to 1 year
|
Prevalence of cholestasis is defined as the proportion of participants who have had at least 1 case of cholestasis within 1 year of Day 1 (baseline). |
Up to 1 year
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Genetic variants of MTM1
Zeitfenster: Up to Week 48
|
The association between genetic variants of MTM1 and cholestasis will be evaluated. |
Up to Week 48
|
|
Risk of cholestasis temporarily associated with environmental modifiers
Zeitfenster: Up to Week 48
|
Medication use, immunization history, infectious disease history and dietary habits will be collected. |
Up to Week 48
|
|
Hospitalizations
Zeitfenster: Up to Week 48
|
Frequency and reason for hospitalizations will be collected. |
Up to Week 48
|
|
Duration of Hospitalizations
Zeitfenster: Up to Week 48
|
Duration of hospitalization visits will be collected. |
Up to Week 48
|
|
Emergency room visits
Zeitfenster: Up to Week 48
|
Frequency and reason for visit will be collected. |
Up to Week 48
|
|
Hepatology specialist visits
Zeitfenster: Up to Week 48
|
Frequency and reason for visit will be collected. |
Up to Week 48
|
|
Scheduled/unscheduled office visits
Zeitfenster: Up to Week 48
|
Frequency and reason for visit will be collected. |
Up to Week 48
|
|
Non-study-specified home healthcare visits
Zeitfenster: Up to Week 48
|
Frequency and reason for visit will be collected. |
Up to Week 48
|
|
Surgeries/procedures
Zeitfenster: Up to Week 48
|
Frequency and type will be collected. |
Up to Week 48
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Studienleiter: Medical Director, Astellas Gene Therapies
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 1600-MA-3536
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .